The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines

키워드

참고문헌 (69)

1. Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care", Can J Psychiatry, 61, pp.510~523 (2016)
2. Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders : major depression summary", Bipolar Disord, 22, pp.788~804 (2020)
3. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
4. Kyung Ho Lee, "A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat", Clinical Psychopharmacology and Neuroscience, 19(1), pp.160~165 (2021), 대한정신약물학회[DOI]
5. Sueki A, "Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?", Neuropsychiatr Dis Treat, 12, pp.1269~1273 (2016)
6. Chiara Fabbri, "How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach", Clinical Psychopharmacology and Neuroscience, 18(4), pp.484~492 (2020), 대한정신약물학회[DOI]
7. 우영섭, "Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients", Clinical Psychopharmacology and Neuroscience, 14(1), pp.1~16 (2016), 대한정신약물학회
8. Woo YS, "Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders : a literature review", Int J Mol Sci, 17, pp.80~ (2016)
9. Mosiołek A, "Effects of antidepressant treatment on peripheral biomarkers in patients with major depressive disorder(MDD)", J Clin Med, 10, pp.1706~ (2021)
10. American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder" (2009), American Psychiatric Association
11. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015", World J Biol Psychiatry, 16, pp.76~95 (2015)
12. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
13. National Collaborating Centre for Mental Health (Great Britain), "Depression: the treatment and management of depression in adults", National Collaborating Centre for Mental Health, ~ (2010)
14. Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 55, pp.7~117 (2021)
15. Suehs B, "Texas medication algorithm project procedural manual. Major depressive disorder algorithms", Texas Department of State Health Services, ~ (2008)
16. Bauer M, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders, part 1 : update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)
17. Cleare A, "Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2008British Association for Psychopharmacology guidelines", J Psychopharmacol, 29, pp.459~525 (2015)
18. Lee MS, "The Korean Medication Algorithm for Major Depressive Disorder(KMA-MDD) : report of the Korean Society of Depressive and Bipolar Disorders", Int J Psychiatry Clin Pract, 10, pp.186~194 (2006)
19. 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
20. Seo JS, "The Korean Medication Algorithm for Depressive Disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
21. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
22. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary", Clinical Psychopharmacology and Neuroscience, 19(4), pp.751~772 (2021), 대한정신약물학회[DOI]
23. 왕희령, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", PSYCHIATRY INVESTIGATION, 11(1), pp.1~11 (2014), 대한신경정신의학회
24. Hee Ryung Wang, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 15(3), pp.199~209 (2017), 대한정신약물학회[DOI]
25. Montgomery SA, "Guidelines for treating depressive illness with antidepressants : a statement from the British Association for Psychopharmacology", J Psychopharmacol, 7(1 Suppl), pp.19~23 (1993)
26. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology", J Psychopharmacol, 14, pp.3~20 (2000)
27. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2000British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
28. Parikh SV, "Clinical guidelines for the treatment of depressive disorders. I. Definitions, prevalence, and health burden", Can J Psychiatry, 46(Suppl 1), pp.13S~20S (2001)
29. Reesal RT, "Clinical guidelines for the treatment of depressive disorders. II. Principles of management", Can J Psychiatry, 46(Suppl 1), pp.21S~28S (2001)
30. Segal ZV, "Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy", Can J Psychiatry, 46(Suppl 1), pp.29S~37S (2001)
31. Kennedy SH, "Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments", Can J Psychiatry, 46(Suppl 1), pp.38S~58S (2001)
32. Segal ZV, "Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy", Can J Psychiatry, 46(Suppl 1), pp.59S~62S (2001)
33. Thorpe L, "Clinical guidelines for the treatment of depressive disorders. VI. Special populations", Can J Psychiatry, 46(Suppl 1), pp.63S~76S (2001)
34. Enns MW, "Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity", Can J Psychiatry, 46(Suppl 1), pp.77S~90S (2001)
35. Patten SB, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management", J Affect Disord, 117(Suppl 1), pp.S5~S14 (2009)
36. Parikh SV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication", J Affect Disord, 117(Suppl 1), pp.S15~S25 (2009)
37. Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy", J Affect Disord, 117(Suppl 1), pp.S26~S43 (2009)
38. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT)clinical guidelines for the management of major depressive disorder in adults. Introduction", J Affect Disord, 117(Suppl 1), pp.S1~S2 (2009)
39. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies", J Affect Disord, 117(Suppl 1), pp.S44~S53 (2009)
40. Ravindran AV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments", J Affect Disord, 117(Suppl 1), pp.S54~S64 (2009)
41. Lam RW, "Canadian Network for Mood and Anxiety Treatments(CANMAT)2016 clinical guidelines for the management of adults with major depressive disorder : introduction and methods", Can J Psychiatry, 61, pp.506~509 (2016)
42. Parikh SV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments", Can J Psychiatry, 61, pp.524~539 (2016)
43. Milev RV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder:section 4. Neurostimulation treatments", Can J Psychiatry, 61, pp.561~575 (2016)
44. Ravindran AV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder:section 5. Complementary and alternative medicine treatments", Can J Psychiatry, 61, pp.576~587 (2016)
45. MacQueen GM, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly", Can J Psychiatry, 61, pp.588~603 (2016)
46. Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
47. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP)guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder", World J Biol Psychiatry, 3, pp.5~43 (2002)
48. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions", World J Biol Psychiatry, 3, pp.69~86 (2002)
49. Bauer M, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders in primary care", World J Biol Psychiatry, 8, pp.67~104 (2007)
50. Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, (Spec No), pp.1~104 (2000)
51. Kriston L, "Efficacy and acceptability of acute treatments for persistent depressive disorder : a network meta-analysis", Depress Anxiety, 31, pp.621~630 (2014)
52. von WolffA, "Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia : a systematic review and meta-analysis", J Affect Disord, 144, pp.7~15 (2013)
53. Tignol J, "Paroxetine in the treatment of melancholia and severe depression", Int Clin Psychopharmacol, 7, pp.91~94 (1992)
54. Entsuah AR, "Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients : a meta-analysis", Psychopharmacol Bull, 31, pp.759~766 (1995)
55. Angst J, "Efficacy of moclobemide in different patient groups: a meta-analysis of studies", Psychopharmacology (Berl), 106(Suppl), pp.S109~S113 (1992)
56. Perry PJ, "Pharmacotherapy for major depression with melancholic features : relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants", J Affect Disord, 39, pp.1~6 (1996)
57. Anderson IM, "Meta-analytical studies on new antidepressants", Br Med Bull, 57, pp.161~178 (2001)
58. Gillman PK, "Revitalizing monoamine oxidase inhibitors : a call for action", CNS Spectr, 25, pp.452~454 (2020)
59. Dickstein DP, "Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation", J Child Adolesc Psychopharmacol, 19, pp.61~73 (2009)
60. Baweja R, "The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit", hyperactivity disorder and disruptive mood dysregulation disorder across home and school, 2016, pp.26, 154~163
61. Pan PY, "Aripiprazole", methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit, J Child Adolesc Psychopharmacol, pp.2018, 28[DOI]
62. Cipriani A, "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents : a network meta-analysis", Lancet, 388, pp.881~890 (2016)
63. Wagner KD, "A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression", J Am Acad Child Adolesc Psychiatry, 45, pp.280~288 (2006)
64. Luxton R, "Depression in children and young people : identification and management NICE guidelines", Arch Dis Child Educ Pract Ed (2021)[DOI]
65. Ghaemi SN, ""Cade’s disease"and beyond : misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder", Can J Psychiatry, 47, pp.125~134 (2002)
66. Hetrick SE, "Newer generation antidepressants for depressive disorders in children and adolescents", Cochrane Database Syst Rev, 11, pp.CD004851~ (2012)
67. Konstantinou GN, "A systematic review of non-invasive neurostimulation for the treatment of depression during pregnancy", J Affect Disord, 272, pp.259~268 (2020)
68. Damar U, "Safety and tolerability of repetitive transcranial magnetic stimulation during pregnancy : a case report and literature review", J Clin Neurophysiol, 37, pp.164~169 (2020)
69. Po-Han Chou, "Personalization of Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder According to the Existing Psychiatric Comorbidity", Clinical Psychopharmacology and Neuroscience, 19(2), pp.190~205 (2021), 대한정신약물학회[DOI]

관련 논문AI추천